Document:

Exhibit 10.2

 

PATENT LICENCE (ADAIR PATENT RIGHTS) (MEDI-493)

 VARIATION
AGREEMENT

 

THIS VARIATION
AGREEMENT entered into this                24th               day
of June 2005 by and between CELLTECH R&D LIMITED (registered in
England No. 1472269) whose principal place of business is at 208 Bath Road,
Slough, Berkshire, SL1 3WE, England (“Celltech”) and UCB S.A. (Register of
Commerce No. 85.078/Company No. 0403 053 608) whose registered office is at 60
Allee de la Recherche, B-1070 Brussels, Belgium and whose UK branch is
registered in England (registered No. BR007969) and situate at 208 Bath Road,
Slough, Berkshire, SL1 3WE (“UCB”) and MEDIMMUNE, INC., a company incorporated
under the laws of the state of Delaware, United States of America, having its
principal place of business at One MedImmune Way, Gaithersburg, MD 20878 (“Licensee”).

 

WHEREAS:

 

(A)                              On 19 January 1998
Celltech and the Licensee entered into the Patent Licence Agreement under the
terms of which Celltech granted and the Licensee accepted a worldwide licence
under the Adair Patent Rights.  On 27 May
2005 Celltech assigned all of the Adair Patent Rights to UCB together with the
benefit and burden of the Patent Licence Agreement.

 

(B)                                On 30 January 2004,
the Licensee commenced legal proceedings against Celltech in the District Court
for the District of Columbia in the USA seeking declarations of
non-infringement and invalidity of the ‘927 Patent (Action No.
1:04CV00143(RWR)).

 

(C)                                On 6 August 2004,
the parties submitted a Joint Rule 26(f) Report in Action No. 1:04CV00143(RWR).  The
Court entered an initial scheduling order on 5 November 2004, setting
forth deadlines leading up to a claim construction hearing.  On 6 December 2004, the parties
exchanged expert reports on issues relating to claim construction.  Claim construction briefing was completed on
17 March 2005, and a claim construction hearing took place on 18 May
2005.  On 8 April 2005, MedImmune
filed a motion for summary judgment that the claims of the ‘927 Patent are
invalid for

 

1

 

lack of
enablement.  Briefing on MedImmune’s
motion was completed on 10 May 2005.  On
29 April 2005, Celltech filed a cross-motion for summary judgment that the
claims of the ‘927 Patent meet the enablement requirement.  Briefing on Celltech’s cross-motion was
completed on 7 June 2005.  Discovery
has been ongoing.

 

(D)                               On 18 March 2004,
Celltech commenced legal proceedings against the Licensee in the High Court of
Justice in England seeking payment of royalties under the Patent Licence
Agreement for the Licensee’s sales of SYNAGIS (Claim No. HC04C00999).  The trial of the action took place before Mr
Justice Laddie from 18 to 23 March 2005. 
At the parties’ request no judgment has been handed down and on 10 June 2005
Mr Justice Laddie confirmed in writing to the parties that he would not deliver
judgment or make any other public statement concerning the action.

 

(E)                                 In
order to avoid the expense, distraction and uncertainty of further litigation
of the matter and for the convenience of the parties, the parties wish to
settle both sets of legal proceedings by way of variation to the Patent Licence
Agreement on the terms set out below.

 

IN
CONSIDERATION of the mutual obligations set out below IT IS AGREED AS FOLLOWS:

 

1.                                      DEFINITIONS

 

In this
Variation Agreement:

 

1.1         “Patent
Licence Agreement” shall mean the patent licence agreement (Adair Patent
Rights) (MEDI-493) entered into on 19 January 1998 between Celltech and
the Licensee.

 

1.2         Words and phrases defined in
Clause 1 of the Patent Licence Agreement shall have the same meaning in this
Variation Agreement EXCEPT where varied as set out below.

 

1.3         “927 Patent” shall mean US
Patent No. 6,632,927 B2 (one of the Adair Patent Rights).

 

1.4         “SYNAGIS” shall mean the
Licensee’s SYNAGIS product, more particularly described in Schedule 1 to
this Variation Agreement.

 

2

 

2.                                      AMENDMENT

 

2.1         Clause
1.8 of the Patent Licence Agreement shall be amended as follows:

 

after “(MEDI-493)”
insert:

 

“including, for the avoidance of doubt,
SYNAGIS”

 

2.2         Clause
3.3 of the Patent Licence Agreement shall be amended as follows (amendments are
underlined):

 

“3.3                                               (a) In further consideration of the
licences granted in Clause 2 the Licensee shall pay to Celltech a royalty at
the following rates of Net Receipts from all Products sold where the
manufacture or sale of the Product in a country of the Territory would, but for
the license granted hereby, infringe a Valid Claim:

 

3.3.1                        [***]

 

3.3.2                        [***]

 

(b) The parties agree that the manufacture or sale of
SYNAGIS in the USA would, but for the license granted hereby, infringe a Valid
Claim of the ‘927 Patent and therefore that the Licensee shall pay to Celltech
a royalty at the rates set forth in Clause 3.3(a) of Net Receipts from SYNAGIS
manufactured or sold in the USA.

 

(c) The Licensee shall pay a royalty for SYNAGIS under
this Clause 3.3 only with respect to SYNAGIS manufactured or sold in the
USA.  The parties agree that in the event
that the Licensee terminates the Patent Licence Agreement, this Clause 3.3(c)
shall survive such termination until the expiry of the ‘927 Patent or the ‘927
Patent is declared invalid or unenforceable in an unappealed or unappealable
decision of a court or competent body having jurisdiction thereof.

 

(d) For the avoidance of doubt, no royalty shall be
due under this Clause 3.3 with respect to SYNAGIS manufactured and sold outside
of the USA.

 

3

 

(e) Further for the avoidance of doubt, no royalty
shall be due under this Clause 3.3 with respect to Product sold by the Licensee
prior to 1 July 2005 provided that between the date of execution of this
Variation Agreement and 1 July 2005 the Licensee shall continue to conduct
its business relating to SYNAGIS in the normal way and shall not offer any
extraordinary inducements, discounts or any other scheme which would expedite
the sales of SYNAGIS between the date of execution of this Variation Agreement
and 1 July 2005.”

 

3.                                      EFFECTIVE DATE

 

This Variation
Agreement shall have effect from the Commencement Date of the Patent Licence
Agreement.

 

4.                                       DISCONTINUANCE OF LEGAL PROCEEDINGS

 

4.1         The
parties shall undertake all steps to ensure that the legal proceedings under UK
Claim No. HC04C00999 and US Action No. 1:04CV00143 (RWR) are discontinued with
both parties bearing their own costs.

 

4.2         The
parties agree to dismiss US Action No. 1:04CV00143 (RWR) with prejudice in
accordance with Schedule 2 to this Variation Agreement.

 

4.3         The
parties shall undertake all steps to procure that no judgment or decision is
issued in either set of legal proceedings referred to in Clause 4.1 above.

 

4.4         Neither
the Licensee nor any of its affiliates (each a “MedImmune Party”) shall, in
connection with any actual, threatened or anticipated dispute between the
parties to this agreement relating to SYNAGIS, challenge the validity or
enforceability of, or seek to narrow the issued claims, scope or duration of,
any claims of the ‘927 Patent, including, without limitation, any
reexaminations or other proceedings in the US Patent and Trademark Office. [***]

 

4

 

5.                                      INTEGRATION OF VARIATION AGREEMENT AND GOVERNING LAW

 

5.1         This Variation Agreement
together with the Patent Licence Agreement constitutes the entire agreement and
understanding of the parties and supersedes all prior oral or written
agreements, understandings or arrangements relating to the subject matter of
either agreement.  Neither party shall be
entitled to rely on any agreement, understanding or arrangement which is not
expressly set forth in this Variation Agreement or in the Patent Licence
Agreement.

 

5.2         This Variation Agreement
shall not be amended, modified, varied or supplemented except in writing signed
by duly authorised representatives of the parties.

 

5.3         The
validity, construction and performance of this Variation Agreement shall be
governed by English law.

 

5.4         All
disputes, claims or proceedings between the parties relating to the validity,
construction or performance of this Variation Agreement shall be subject to the
jurisdiction of the laws of England to the jurisdiction of whose courts the
parties hereto submit.  Each of the
parties consents to the award or grant of any relief in any such proceedings
before the High Court of Justice in England. 
Either party shall have the right to take proceedings in any other
jurisdiction for the purposes of enforcing a judgment or order obtained from a
Court of Justice in England.

 

IN WITNESS
whereof, this Variation Agreement has been executed by duly authorised
representatives of the parties on the year first above written.

 

 

	
  SIGNED by

  	
  /s/

  	
   

  
	
  for and on behalf of

  	
   

  
	
  CELLTECH
  R&D LIMITED

  	
  Name:

  	
   

  	
   

  
	
   

  	
  Position:

  	
   

  	
   

  
					

 

5

 

	
  SIGNED
  by

  	
  /s/

  	
   

  
	
  for and on behalf of

  	
   

  
	
  UCB S.A.

  	
  Name:

  	
   

  	
   

  
	
   

  	
  Position:

  	
   

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  SIGNED
  by

  	
  /s/

  	
   

  
	
  for and on behalf of

  	
   

  
	
  MEDIMMUNE, INC.

  	
  Name:

  	
   

  	
   

  
	
   

  	
  Position:

  	
   

  	
   

  
					

 

6Exhibit 4.2

 

[Union Electric
Company Letterhead]

 

Company Order

 

July 21, 2005

 

The Bank of New York

101 Barclay Street

Floor 21W

New York, New York 10286

 

Ladies and Gentlemen:

 

Application is hereby
made to The Bank of New York, a New York banking corporation, as trustee (the “Trustee”),
under the Indenture dated as of August 15, 2002 (the “Indenture”), between
Union Electric Company, a Missouri corporation (the “Company”), and the Trustee
for the authentication and delivery of $300,000,000 aggregate principal amount
of the Company’s 5.30% Senior Secured Notes due 2037 (the “Notes”), pursuant to
the provisions of Article II of the Indenture. 
On or after the Release Date, the Company, in its discretion, may change
the descriptive title of the Notes to delete the word “Secured” from such
descriptive title.  Additional Notes
without limitation as to amount, and without the consent of the holders of the
then Outstanding Notes, may also be authenticated and delivered in the manner
provided in Section 2.05 of the Indenture. 
All capitalized terms not defined herein which are defined in the
Indenture shall have the same meaning as used in the Indenture.

 

In connection with this
Company Order, there are delivered to you herewith the following:

 

1.               Certified copies of
the resolutions adopted by the Board of Directors of the Company authorizing
this Company Order and the issuance and sale of the Notes by the Company
pursuant to Section 2.05(c)(1) of the Indenture;

 

2.               Opinions of Counsel
addressed to you or in which it is stated that you may rely pursuant to Section
2.05(c)(2) of the Indenture;

 

3.               Expert’s
certificate pursuant to Section 2.05(c)(3) of the
Indenture;

 

4.               Officers’
Certificate pursuant to Section 2.05(c)(4) of the
Indenture;

 

5.               A Global Note
representing the Notes and, pursuant to Section 2.05(c) of the Indenture,
specifying the terms of the Notes (which terms are incorporated by reference
herein) executed on behalf of the Company in accordance with the terms of
Section 2.05(a) of the Indenture; and

 

 

6.               Pursuant to Section
2.05(c)(3) of the Indenture, the Company’s First Mortgage Bonds designated “First
Mortgage Bonds, Senior Notes Series II” (the “First Mortgage Bonds”) in the
principal amount of $300,000,000 relating to the Notes, fully registered in the
name of the Trustee in trust for the benefit of the Holders from time to time
of such Notes.

 

You are hereby instructed
to authenticate the Global Note representing the Notes and deliver it to The
Depository Trust Company (“DTC”) or its custodian.  The Global Note representing the Notes is to
be held for delivery to Citigroup Global Markets Inc. and Lehman Brothers Inc.,
on behalf of the several underwriters, against payment therefor at the closing
in respect of the sale thereof, such closing to be held at 10:00 a.m., New York
time, July 21, 2005, at the offices of Pillsbury Winthrop Shaw Pittman LLP,
1540 Broadway, New York, NY 10036.

 

 

Please acknowledge
receipt of the Global Note representing the Notes, the instructions referred to
above and the supporting documentation pursuant to the Indenture referred to
above.

 

 

	
   

  	
  Very truly yours,

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  Union Electric Company

  
	
   

  	
  (d/b/a AmerenUE)

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By: 

  	
  /s/ Jerre E.
  Birdsong

  	
   

  
	
   

  	
   

  	
  Name:  Jerre
  E. Birdsong

  
	
   

  	
   

  	
  Title:  Vice
  President and Treasurer

  

 

 

Receipt from the Company
of the Global Note representing the Notes, certain instructions related thereto
and the supporting documentation pursuant to the Indenture, including the First
Mortgage Bonds in trust for the benefit of the Holders in connection with the authentication
and delivery of the Notes is hereby acknowledged.

 

 

	
   

  	
  The Bank of New York,

  
	
   

  	
  as Trustee

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Van K. Brown

  	
   

  
	
   

  	
   

  	
  Name: Van K. Brown

  
	
   

  	
   

  	
  Vice President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00087-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00087-of-00352.parquet"}]]